Latest news
Sciety invests in cutting-edge biotech company NEOGAP Therapeutics
PRESS RELEASE. Sciety recently made an investment of over SEK 58 million in the cell therapy company NEOGAP Therapeutics, which…
Read moreSciety invests in Synartro that develops novel therapy for osteoarthritis
PRESS RELEASE. The Swedish biotechnology company Synartro, which is developing a novel, improved treatment for knee osteoarthritis, has successfully raised…
Read more
The investment syndicate
Join the Sciety investment syndicate and receive personal invitations to company presentation events and be the first to get exclusive information about selected companies. Sciety membership is free and a minimum investment is SEK 100,000.
Read more about the Sciety investment syndicate and membership
Services we offer
Sciety offers capital market services with a focus on Swedish life science. Based on extensive industry experience, we offer services to investors, growth companies and industrial players within life science.
What our clients say
“We are very pleased with the outcome of the financing round through Sciety. The whole process was efficient and went very smoothly thanks to Sciety's competent and professional team. It was a fun and constructive collaboration.”
Malte Kühnemund, CEO Cartana
Investment areas
Biotechnology
From late preclinical trial phase to Phase II clinical trials. All therapeutic areas.
Medical technology
From clinical validation phase to expansion phase.
Pharmacology
From late preclinical phase to Phase II clinical trials. All therapeutic areas.
Diagnostics
From clinical validation to expansion phase. All indications.
ICT in healthcare
From pilot phase to expansion phase. Value-enhancing healthcare.
Health tech
From early sales to expansion phase. Preventive health and medical services.
Companies open for investments
We do not have any companies open for investments at the moment. Sign up to receive an email once something new is coming up.
Selection of executed investments
Pharmnovo AB
PharmNovo develops a novel drug for nerve pain, where there is a high, unmet need for effective and safe treatments. The candidate PN6047 shows effective pain relief in animal models, without the negative side effects associated with existing drugs.
Read more
NEOGAP Therapeutics AB
NEOGAP has a unique approach to train the patient’s immune system to target tumour-specific mutations, so called neoantigens to eradicate the cancer. The treatment has the potential to kill the cancer cells while leaving healthy cells untouched, which significantly reduces the risk of side effects.
Read more
